Clinical cancer advances 2012: Annual report on progress against cancer from the American Society of Clinical Oncology

Journal of Clinical Oncology

Volumn 31, Issue 1, 2013, Pages 131-161

  Roth, Bruce J ^a   Krilov, Lada ^b   Adams, Sylvia ^c   Aghajanian, Carol A ^d   Bach, Peter ^d   Braiteh, Fadi ^e   Brose, Marcia S ^g   Ellis, Lee M ^h   Erba, Harry ⁱ   George, Daniel J ^j   Gilbert, Mark R ^h   Jacobson, Joseph O ^k   Larsen, Eric C ^l   Lichtman, Stuart M ^d   Partridge, Ann H ^k   Patel, Jyoti D ^m   Quinn, David I ^o   Robison, Leslie L ^p   Von Roenn, Jamie H ⁿ   Samlowski, Wolfram ^f   Schwartz, Gary K ^d   Vogelzang, Nicholas J ^e   more..

^a WASHINGTON UNIVERSITY   (United States)

^b AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e Department of Hematology Oncology   (United States)

^f NEVADA CANCER INSTITUTE   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^j DUKE UNIVERSITY MEDICAL CENTER   (United States)

^k DANA FARBER CANCER INSTITUTE   (United States)

^l MAINE MEDICAL CENTER   (United States)

^m NORTHWESTERN UNIVERSITY   (United States)

ⁿ NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^o UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^p ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; AXITINIB; BORTEZOMIB; CABOZANTINIB; CARFILZOMIB; CETUXIMAB; CRIZOTINIB; DOCETAXEL; ENZALUTAMIDE; EVEROLIMUS; EXEMESTANE; FLUOROURACIL; FOLINIC ACID; IBRUTINIB; IMATINIB; IRINOTECAN; LAPATINIB; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; PERTUZUMAB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; REGORAFENIB; TRASTUZUMAB; UNINDEXED DRUG; VINCRISTINE SULFATE; VISMODEGIB;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT DISEASE; ADVANCED CANCER; ALCOHOL CONSUMPTION; BASAL CELL CARCINOMA; BREAST CANCER; CANCER DIAGNOSIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER RESISTANCE; CANCER SCREENING; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CHILDHOOD CANCER; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLON CANCER; COLORECTAL CANCER; CONFERENCE PAPER; DIARRHEA; DRUG INDICATION; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL STROMAL TUMOR; GLIOMA; HAIR LOSS; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LEUKEMIA; LIVER CANCER; LUNG NON SMALL CELL CANCER; MEDICAL SOCIETY; MELANOMA; MOUTH CANCER; MULTIPLE MYELOMA; MUSCLE CRAMP; NEUROBLASTOMA; OLIGODENDROGLIOMA; ONCOLOGY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; SARCOMA; SIDE EFFECT; SMOKING; SOFT TISSUE SARCOMA; STEM CELL TRANSPLANTATION; THYROID MEDULLARY CARCINOMA; TREATMENT RESPONSE; UNITED STATES; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; WEIGHT REDUCTION;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; EARLY DETECTION OF CANCER; HEALTH POLICY; HUMANS; INDIVIDUALIZED MEDICINE; MEDICAL ONCOLOGY; NEOPLASMS; RESEARCH REPORT; TIME FACTORS;

EID: 84871812256     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.47.1938     Document Type: Conference Paper

References (112)

1. Kris MG, Meropol NJ, Winer EP (eds): Accelerating progress against cancer: ASCO's blueprint for transforming clinical and translational cancer research. http://www.asco.org/ASCOv2/Department%20Content/ Cancer%20Policy%20and%20Clinical%20Affairs/Downloads/Blueprint.pdf
2. Attal M, Lauwers-Cances V, Marit G, et al: Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 366:1782-1791, 2012
3. Palumbo A, Hajek R, Delforge M, et al: Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 366:1759-1769, 2012
4. Castaigne S, Pautas C, Terré C, et al: Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): A randomised, open-label, phase 3 study. Lancet 379:1508-1516, 2012
5. Rummel MJ, Niederle N, Maschmeyer G, et al: Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study. J Clin Oncol 30:6s, 2012 (suppl; abstr 3)
6. Cortes JE, Dong-Wook K, Pinilla-Ibarz J, et al: PACE: A pivotal phase II trial of ponatinib in patients with CML and Ph+ ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation. J Clin Oncol 30:395s, 2012 (suppl; abstr 6503)
7. Byrd JC, Furman RR, Coutre SE, et al: The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): Interim results of a phase Ib/II study. J Clin Oncol 30:417s, 2012 (suppl; abstr 6507)
8. Topp M, Goekbuget N, Zugmaier G, et al: Effect of anti-CD19 BiTE blinatumomab on complete remission rate and overall survival in adult patients with relapsed/refractory B-precursor ALL. J Clin Oncol 30:416s, 2012 (suppl; abstr 6500)
9. US Food and Drug Administration: FDA approves Kyprolis for some patients with multiple myeloma. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm312920.htm
10. US Food and Drug Administration: FDA approves Marqibo to treat rare type of leukemia. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm315027.htm
11. Verma S, Miles D, Gianni L, et al: Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med [epub ahead of print on October 1, 2012]
12. Baselga J, Cortés J, Kim SB, et al: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109-119, 2012
13. US Food and Drug Administration: Pertuzumab. http://www.fda.gov/Drugs/ InformationOnDrugs/ApprovedDrugs/ucm307592.htm
14. Baselga J, Campone M, Piccart M, et al: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520-529, 2012
15. USFood and Drug Administration: FDA approves Afinitor for advanced breast cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312965.htm
16. Baselga J, Bradbury I, Eidtmann H, et al: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial. Lancet 379:633-640, 2012
17. Ellis MJ, Ding L, Shen D, et al: Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486:353-360, 2012
18. Curtis C, Shah SP, Chin SF, et al: The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486:346-352, 2012
19. Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumors. Nature 490:61-70, 2012
20. Cairncross GJ, Wuang M, Shaw EG, et al: Chemotherapy plus radiotherapy (CT-RT) versus RT alone for patients with anaplastic oligodendroglioma: Long-term results of the RTOG 9402 phase III study. J Clin Oncol 30:117s, 2012 (suppl; abstr 2008b)
21. Van Den Bent MJ, Hoang-Xuan K, Brandes AA, et al: Long-term follow-up results of EORTC 26951: A randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD). J Clin Oncol 30:5s, 2012 (suppl; abstr 2)
22. Wick W, Platten M, Meisner C, et al: Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: The NOA-08 randomised, phase 3 trial. Lancet Oncol 13:707-715, 2012
23. Trippa L, Lee EQ, Wen PY, et al: Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. J Clin Oncol 30:3258-3263, 2012
24. Gilbert MR, Gonzalez J, Hunter K, et al: Randomized phase II 8-arm factorial study of adjuvant dose-dense (dd) temozolomide (TMZ) with permutations of thalidomide (Thal), isotretinoin (CRA), and/or celecoxib (Cel) for newly diagnosed glioblastoma (GBM). J Clin Oncol 30:115s, 2012 (suppl; abstr 2003)
25. van Hagen P, Hulshof MC, Lanschot JJ, et al: Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074-2084, 2012
26. Grothey A, Sobrero AF, Siena S, et al: Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies. J Clin Oncol 30, 2012 (suppl 4; abstr LBA385)
27. US Food and Drug Administration: FDA approves new treatment for advanced colorectal cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm321271.htm
28. Arnold D, Andre T, Bennouna J, et al: Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study). J Clin Oncol 30:203s, 2012 (suppl; abstr CRA3503)
29. Alberts SR, Sargent DJ, Nair S, et al: Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: A randomized trial. JAMA 307:1383-1393, 2012
30. Sorbye H, Mauer M, Gruenberger T, et al: Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann Surg 255:534-539, 2012
31. US Food and Drug Administration: Cetuximab in combination with Folfiri/Therascreen. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ ucm310933.htm
32. US Food and Drug Administration: FDA Approves Zaltrap for metastatic colorectal cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm314372.htm
33. Scher HI, Fizazi K, Saad F, et al: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187-1197, 2012
34. US Food and Drug Administration: FDA approves new treatment for a type of late stage prostate cancer. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm317838.htm
35. Ryan CJ, Smith MR, De Bono, JS, et al: Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 30:281s, 2012 (suppl; abstr LBA4518)
36. Hussain M, Tangen CM, Higano CS, et al: Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial. J Clin Oncol 30:6s, 2012 (suppl; abstr 4)
37. Crook JM, O'Callaghan CJ, Duncan G, et al: Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 367:895-903, 2012
38. Parker C, Heinrich D, O'Sullivan JM, et al: Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). J Clin Oncol 30:280s, 2012 (suppl; abstr LBA4512)
39. Parker C, Coleman RE, Nilsson S, et al: Updated survival, quality of life (QOL), and safety data of Radium-223 chloride (RA-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases from the phase 3 double-blind, randomized, multinational study (ALSYMCA). Presented at the 2012 European Society for Medical Oncology Congress, Vienna, Austria, September 28-October 2, 2012 (abstr 898PD)
40. USFood and Drug Administration: FDA approves Inlyta to treat patients with a type of advanced kidney cancer. http://www.fda.gov/Newsevents/Newsroom/ PressAnnouncements/ucm289423.htm
41. Gordon AN, Fleagle JT, Guthrie D, et al: Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312-3322, 2001
42. ten Bokkel Huinink W, Gore M, Carmichael J, et al: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15:2183-2193, 1997
43. Pujade-Lauraine E, Hilpert F, Weber B, et al: AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol 30:327s, 2012 (suppl; abstr LBA5002)
44. Bell D, Berchuck A, Birrer M, et al: Integrated genomic analysis of ovarian carcinoma. Nature 474:609-615, 2011
45. Bolton KL, Chenevix-Trench G, Goh C, et al: Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 307:382-390, 2012
46. Alsop K, Fereday S, Meldrum C, et al: BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Australian Ovarian Cancer Study Group. J Clin Oncol 30:2654-2663, 2012
47. Miller D, Filliaci V, Fleming G, et al: Late-breaking abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 125:771-773, 2012
48. Kitagawa R, Katsumata N, Shibata T, et al: A randomized, phase III trial of paclitaxel plus carboplatin (TC) versus paclitaxel plus cisplatin (TP) in stage IVb, persistent or recurrent cervical cancer: Japan Clinical Oncology Group study (JCOG0505). J Clin Oncol 30:328s, 2012 (suppl; abstr 5006)
49. Schoffski P, Elisei R, Müller S, et al: An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. J Clin Oncol 30:358s, 2012 (suppl; abstr 5508)
50. Loh Ho A, Leboeuf R, Grewal RK, et al: Reacquisition of RAI uptake in RAI-refractory metastatic thyroid cancers by pretreatment with the MEK inhibitor selumetinib. J Clin Oncol 30:358s, 2012 (suppl; abstr 5509)
51. Stoehlmacher-Williams J, Villanueva C, Foa P, et al: Safety and efficacy of panitumumab (pmab) in HPV-positive (+) and HPV-negative (-) recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Analysis of the global phase III SPECTRUM trial. J Clin Oncol 30:357s, 2012 (suppl; abstr 5504)
52. Li Y, Li L: Intra-arterial infusion of recombinant adenoviral human p53 gene combined chemotherapy for advanced oral cancer: A phase II double-blind randomized clinical trial. J Clin Oncol 30:357s, 2012 (suppl; abstr 5507)
53. Lilenabaum R, Zukin M, Pereira JR, et al: A randomized phase III trial of single-agent pemetrexed (P) versus carboplatin and pemetrexed (CP) in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2. J Clin Oncol 30:481s, 2012 (suppl; abstr 7506)
54. Janne PA, Shaw AT, Pereira JR, et al: Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC). J Clin Oncol 30:480s, 2012 (suppl; abstr 7503)
55. Paik PK, Hasanovic A, Wang L, et al: Multiplex testing for driver mutations in squamous cell carcinomas of the lung. J Clin Oncol 30:481s, 2012 (suppl; abstr 7505)
56. Shaw AT, Camidge DR, Engelman JA, et al: Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. J Clin Oncol 30:482s, 2012 (suppl; abstr 7508)
57. Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al: Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 366:2180-2188, 2012
58. US Food and Drug Administration: FDA approves new treatment for most common type of skin cancer. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm289545.htm
59. Flaherty LE, Moon J, Atkins MB, et al: Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): An intergroup study of CALGB, COG, ECOG, and SWOG. J Clin Oncol 30:541s, 2012 (suppl; abstr 8504)
60. Hauschild A, Grob JJ, Demidov LV, et al: Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-365, 2012
61. Flaherty KT, Robert C, Hersey P, et al: Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107-114, 2012
62. Flaherty KT, Infante JR, Daud A, et al: Combined BRAF and MEK inhibiton in melanoma with BRAF V600 mutations. N Engl J Med [epub ahead of print on September 29, 2012]
63. Sosman JA, Kim KB, Schuchter L, et al: Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707-714, 2012
64. Brahmer JR, Tykodi SS, Chow LQ, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-2465, 2012
65. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454, 2012
66. Mosse YP, Balis FM, Lim MS, et al: Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: A Children's Oncology Group phase 1 consortium study. J Clin Oncol 30:606s, 2012 (suppl; abstr 9500)
67. Messinger YH, Gaynon PS, Sposto R, et al: Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Blood 120:285-290, 2012
68. Voss SD, Chen L, Constine LS, et al: Surveillance computed tomography imaging and detection of relapse in intermediate- and advanced-stage pediatric Hodgkin's lymphoma: A report from the Children's Oncology Group. J Clin Oncol 30:2635-2640, 2012
69. Larsen E, Raetz EA, Winick NJ, et al: Outcome in adolescent and young adult (AYA) patients compared with younger patients treated for high-risk B-precursor acute lymphoblastic leukemia (HRALL): A report from the Children's Oncology Group study AALL0232. J Clin Oncol 30:608s, 2012 (suppl; abstr CRA9508)
70. Chen IM, Harvey RC, Mullighan CG, et al: Outcome modeling with CRLF2, IKZF1, JAK and minimal residual disease in pediatric acute lymphoblastic leukemia: A Children's Oncology Group study. Blood 119:3515-3522, 2012
71. US Food and Drug Administration: FDA approves Votrient for advanced soft tissue sarcoma. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm302065.htm
72. van der Graaf WT, Blay JY, Chawla SP, et al: Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379:1879-1886, 2012
73. Demetri GD, Reichardt P, Kang YK, et al: Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial. J Clin Oncol 30:632s, 2012 (suppl; abstr LBA10008)
74. Dickson MA, Keohan ML, Tap WD, et al: Phase II trial of the CDK4 inhibitor PD0332991 in CDK4-amplified liposarcoma. J Clin Oncol 30:630s, 2012 (suppl; abstr 10002)
75. Schwartz GK, Tap WD, Qin LX, et al: A phase II multicenter study of the IGF-1 receptor antibody cixutumumab (A12) and the mTOR inhibitor temsirolimus (TEM) in patients (pts) with refractory IGF-1R positive (+) and negative (-) bone and soft tissue sarcomas (STS). J Clin Oncol 30:630s, 2012 (suppl; abstr 10003)
76. US Food and Drug Administration: FDA approves Gleevec for expanded use in patients with rare gastrointestinal cancer. http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm289760.htm
77. Barretina J, Caponigro G, Stransky N, et al: The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity. Nature 483:603-607, 2012
78. Garnett MJ, Edelman EJ, Heidorn SJ, et al: Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483:570-575, 2012
79. Omenn GS, DeAngelis CD, DeMets DL, et al (eds): Evolution of Translational Omics: Lessons Learned and the Path Forward. Washington, DC, Institute of Medicine, 2012
80. Gerlinger M, Rowan AJ, Horswell S, et al: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883-892, 2012
81. Cancer Genome Atlas Network: Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330-337, 2012
82. Liu Y, Sun Y, Broaddus R, et al: Integrated analysis of gene expression and tumor nuclear image profiles associated with chemotherapy response in serous ovarian carcinoma. PLoS ONE 7:e36383, 2012
83. Kang J, D'Andrea AD, Kozono D: A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy. J Natl Cancer Inst 104:1-12, 2012
84. De Carvalho DD, Sharma S, You JS, et al: DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell 21:655-667, 2012
85. Misale S, Yaeger R, Hobor S, et al: Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486:532-536, 2012
86. Prahallad A, Sun C, Huang S, et al: Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR. Nature 483:100-103, 2012
87. Schoen RE, Pinsky PF, Weissfeld JL, et al: Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 366:2345-2357, 2012
88. Oken MM, Hocking WG, Kvale PA, et al: Screening by chest radiograph and lung cancer mortality: The Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA 306:1865-1873, 2011
89. Bach PB, Mirkin JN, Oliver TK, et al: Benefits and harms of CT screening for lung cancer: A systematic review. JAMA 307:2418-2429, 2012
90. Rothwell PM, Price JF, Fowkes FG, et al: Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: Analysis of the time course of risks and benefits in 51 randomized controlled trials. Lancet 379:1602-1612, 2012
91. Navari RM, Nagy CK, Gray SE: The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. J Clin Oncol 30:582s, 2012 (suppl; abstr 9064)
92. Lavoie Smith EM, Pang H, Cirrincione C, et al: CALGB 170601: A phase III double blind trial of duloxetine to treat painful chemotherapy-induced peripheral neuropathy (CIPN). J Clin Oncol 30:570s, 2012 (suppl; abstr CRA9013)
93. Blanco JG, Sun CL, Landier W, et al: Anthracycline-related cardiomyopathy after childhood cancer: Role of polymorphisms in carbonyl reductase gene - A report from the Children's Oncology Group. J Clin Oncol 30:1415-1421, 2012
94. Volandes AE, Paasche-Orlow M, El-Jawahri A, et al: A video decision support tool for CPR in advanced cancer: A randomized controlled trial. J Clin Oncol 30:568s, 2012 (suppl; abstr 9004)
95. Zimmermann C, Swami N, Rodin G, et al: Cluster-randomized trial of early palliative care for patients with metastatic cancer. J Clin Oncol 30:567s, 2012 (suppl; abstr 9003)
96. Breuer B, Fleishman SB, Cruciani RA, et al: Medical oncologists' attitudes and practice in cancer pain management: A national survey. J Clin Oncol 29:4769-4775, 2011
97. Soubeyran P, Fonck M, Blanc-Bisson C, et al: Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol 30:1829-1834, 2012
98. Hurria A, Togawa K, Mohile SG, et al: Predicting chemotherapy toxicity in older adults with cancer: A prospective multicenter study. J Clin Oncol 29:3457-3465, 2011
99. Kanesvaran R, Li H, Koo KN, et al: Analysis of prognostic factors of comprehensive geriatric assessment and development of a clinical scoring system in elderly Asian patients with cancer. J Clin Oncol 29:3620-3627, 2011
100. Blayney DW, Severson J, Martin CJ, et al: Michigan oncology practices showed varying adherence rates to practice guidelines, but quality interventions improved care. Health Aff (Millwood) 31:718-728, 2012
101. Quinten C, Maringwa J, Gotay CC, et al: Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. J Natl Cancer Inst 103:1851-1858, 2011
102. Kolfschoten NE, Gooiker GA, Bastiaannet E, et al: Combining process indicators to evaluate quality of care for surgical patients with colorectal cancer: Are scores consistent with short-term outcome? BMJ Qual Saf 21:481-489, 2012
103. Morden NE, Chang CH, Jacobson JO, et al: End-of-life care for Medicare beneficiaries with cancer is highly intensive overall and varies widely. Health Aff (Millwood) 31:786-796, 2012
104. Stukel TA, Fisher ES, Alter DA, et al: Association of hospital spending intensity with mortality and readmission rates in Ontario hospitals. JAMA 307:1037-1045, 2012
105. Unger JM, Hershman DL, Burg K, et al: Patterns of decision making about cancer clinical trial participation among the online cancer treatment community: A collaboration between SWOG and NexCura. J Clin Oncol 30:384s, 2012 (suppl; abstr CRA6009)
106. Shaw PH, Boyiadzis M, Tawbi H, et al: Improved clinical trial enrollment in adolescent and young adult (AYA) oncology patients after the establishment of an AYA oncology program uniting pediatric and medical oncology divisions. Cancer 118:3614-3617, 2012
107. Parsons HM, Harlan LC, Lynch CF, et al: Impact of cancer on work and education among adolescent and young adult cancer survivors. J Clin Oncol 30:2393-2400, 2012
108. Tai E, Buchanan N, Townsend J, et al: Health status of adolescent and young adult cancer survivors. Cancer 118:4884-4891, 2012
109. Dale W, Mohile SG, Eldadah BA, et al: Biological, clinical, and psychosocial correlates at the interface of cancer and aging research. J Natl Cancer Inst 104:581-589, 2012
110. Institute of Medicine: A national cancer clinical trials system for the 21st century: Reinvigorating the NCI Cooperative Group program. Washington, DC, Institute of Medicine, 2011
111. Institute of Medicine: Best care at lower cost: The path to continuously learning health care in America. Washington, DC, 2012
112. Executive Office of the President, President's Council of Advisors on Science and Technology: Report to the president on propelling innovation in drug discovery, development, and evaluation. http://www.whitehouse.gov/sites/ default/files/microsites/ostp/pcast-fda-final.pdf